Valuation: MiMedx Group, Inc.

Capitalization 1.03B 882M 826M 770M 1.42B 92.37B 1.55B 9.67B 3.73B 43.63B 3.85B 3.77B 160B P/E ratio 2025 *
20.4x
P/E ratio 2026 * 22.8x
Enterprise value 1.03B 882M 826M 770M 1.42B 92.37B 1.55B 9.67B 3.73B 43.63B 3.85B 3.77B 160B EV / Sales 2025 *
2.52x
EV / Sales 2026 * 2.47x
Free-Float
97.55%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.02%
1 week+0.73%
Current month+0.73%
1 month-12.94%
3 months-2.94%
6 months+9.31%
Current year-27.96%
More quotes
1 week 6.62
Extreme 6.62
7.06
1 month 6.32
Extreme 6.325
7.77
Current year 5.79
Extreme 5.79
9.71
1 year 5.79
Extreme 5.79
10.14
3 years 2.43
Extreme 2.43
10.14
5 years 2.43
Extreme 2.43
15.99
10 years 0.95
Extreme 0.95
18.25
More quotes
Manager TitleAgeSince
Chief Executive Officer 61 2023-01-26
Director of Finance/CFO 59 2023-07-04
Chief Tech/Sci/R&D Officer - 2021-05-31
Director TitleAgeSince
Director/Board Member 72 2019-06-18
Chairman 72 2019-06-18
Director/Board Member 62 2019-06-18
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.02%+0.73%-26.82%+121.41% 1.02B
-8.78%-6.82% - - 847M
-4.40%+2.82%+146.92%+108.03% 324M
+0.81%+1.63%+126.36%+16.36% 89.71M
Average -2.84%-0.62%+82.16%+81.93% 569.11M
Weighted average by Cap. -3.40%-0.87%+22.17%+111.78%
See all sector performances

Financials

2025 *2026 *
Net sales 407M 350M 328M 306M 565M 36.67B 614M 3.84B 1.48B 17.32B 1.53B 1.5B 63.33B 416M 358M 335M 312M 577M 37.45B 627M 3.92B 1.51B 17.69B 1.56B 1.53B 64.67B
Net income 48.22M 41.45M 38.83M 36.2M 66.85M 4.34B 72.72M 454M 175M 2.05B 181M 177M 7.49B 49.82M 42.83M 40.12M 37.4M 69.07M 4.48B 75.13M 469M 181M 2.12B 187M 183M 7.74B
Net Debt - -
More financial data * Estimated data
Logo MiMedx Group, Inc.
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.
Employees
837
More about the company
Date Price Change Volume
25-12-05 6.930 $ +1.02% 527,667
25-12-04 6.860 $ -1.44% 669,315
25-12-03 6.960 $ +3.57% 633,937
25-12-02 6.720 $ +0.75% 545,806
25-12-01 6.670 $ -3.05% 723,754

Delayed Quote Nasdaq, December 05, 2025 at 04:00 pm EST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.930USD
Average target price
12.20USD
Spread / Average Target
+76.05%
Consensus

Quarterly revenue - Rate of surprise